Cowen started coverage on shares of Genomic Health (NASDAQ: GHDX) in a research report released on Tuesday morning. The firm issued an outperform rating on the stock.
GHDX has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase reiterated a neutral rating on shares of Genomic Health in a research note to investors on Thursday, September 27th. Separately, analysts at Credit Suisse initiated coverage on shares of Genomic Health in a research note to investors on Monday, September 24th. They set an outperform rating and a $43.00 price target on the stock
and yesterday at the close I sold 700 shares and just bought them back !...... I have trading and long shares.I keep wondering how long I can keep making these quick trades so profitable...we have been in this range for almost 6 months! .... Good Luck to all.